by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB…
By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual…
By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed…
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …
By Khairunisa Suleiman, Technical Co-Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG On Sept. 26, 2018, the world came together at the United Nations General Assembly in New York for the first-ever High-Level Meeting…
By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…
By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in…
With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.
The global system for funding drug development socializes the costs and privatizes the pro ts though a system of taxpayer-funded research, legal corporate tax havens, and intellectual property registrations to guarantee exclusive access to markets and to reduce corporate taxes, while selling identical formulations at wildly different prices.
May 2015 Examples of media coverage: Gilead Sciences (GILD) May Have Found A Cure For HIV! – CNA Finance, May 18, 2015 This Experimental Drug Could Finally Cure HIV – Motley Fool, May 18, 2015 Original source: Unknown, possibly a…